| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.7M | — | +225.3% |
| SG&A Expense | $2.1M | — | +200.0% |
| Operating Income | -$3.8M | — | -210.6% |
| Interest Expense | $100K | — | -80.0% |
| Net Income | -$3.8M | — | -119.7% |
| EPS (Basic) | -$0.08 | — | +82.2% |
| EPS (Diluted) | -$0.08 | — | +82.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.4M | +33.0% | +1314.0% |
| Current Assets | $8.5M | +61.3% | — |
| Total Assets | $8.5M | +61.3% | — |
| Current Liabilities | $16.1M | -6.3% | — |
| Stockholders' Equity | -$7.6M | +36.3% | +70.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.5M | — | -552.9% |
| Financing Cash Flow | $7.0M | — | +912.8% |